FMS - Fresenius Medical Care: Significant Upside Remains

2024-06-25 06:15:27 ET

Summary

• Fresenius Medical Care has underperformed since 2017, declining over 50% in the market.
• Despite the decline, the company remains a market leader in dialysis services with a strong product line.
• The company is actively managing its assets and focusing on deleveraging to strengthen its operations.

Dear readers/followers,

In this article, I'll update you on the case of Fresenius Medical Care ( FMS ), a company I have been covering for several years. This company has not done that great thus far. I typically, when investing in Fresenius, focus on the Fresenius native and main company - FRE on the German stock market. Fresenius Medical Care represents primarily the company's dialysis operations.

While these are attractive, I view them as less diversified than the main company and thus, at a lower overall appeal by comparison. My last official coverage of the company continues, unfortunately, the trend of underperformance because the company has as of yet failed to "pop" with regards to its expectations and forecasts....

For further details see: